Policy & Regulation
Moderna board member steps down to avoid conflict of interest in COVID-19 clinical trial
31 July 2020 -

Moderna Inc (Nasdaq:MRNA), a clinical stage biotechnology company with a focus on messenger RNA (mRNA) therapeutics and vaccines, reported on Thursday the resignation of Dr Elizabeth (Betsy) Nabel from its board of directors to ensure no conflict of interest concerning a clinical trial of the company's vaccine candidate against COVID-19.

Dr Nabel is president of Brigham and Women's Hospital, which is participating as one of 89 clinical trial sites in the Phase 3 trial of Moderna's vaccine candidate mRNA-1273.

"In the context of the start of the 30,000 participant Phase 3 trial for Moderna's COVID-19 vaccine candidate, and Brigham and Women's Hospital's final preparation as a site for enrolling up to 300-500 trial participants, we have accepted Betsy's resignation out of an abundance of caution to avoid any potential of even apparent conflict of interest on her part or Moderna's part," said Noubar Afeyan, co-founder and chairman of Moderna and CEO of Flagship Pioneering.



Related Headlines